Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial
by Pujade-Lauraine, Éric (Author)
, Selle, F. (Author)
, Scambia, G. (Author)
, Asselain, B. (Author)
, Marmé, Frederik (Author)
, Lindemann, K. (Author)
, Colombo, N. (Author)
, Mądry, R. (Author)
, Glasspool, R. (Author)
, Vergote, Ignace B. (Author)
, Korach, J. (Author)
, Lheureux, S. (Author)
, Dubot, C. (Author)
, Oaknin, A. (Author)
, Zamagni, C. (Author)
, Heitz, Florian (Author)
, Gladieff, L. (Author)
, Rubio-Pérez, M. J. (Author)
, Scollo, P. (Author)
, Blakeley, C. (Author)
, Shaw, B. (Author)
, Ray-Coquard, I. (Author)
, Redondo, A. (Author)
,
Call Number:
Loading…
Located:
Loading…
Article (Journal)
Online Resource